Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide versus placebo for transfusion-dependent myelofibrosis
2010-018965-42Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2010
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more comparing Pomalidomide with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving at least 84 consecutive days of red blood cell transfusion independence. Started Oct 2010; status: completed.
02
Drugs
pomalidomide
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2010-018965-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018965-42.